A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel (Registered Trademark) + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria.

Trial Profile

A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel (Registered Trademark) + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2011

At a glance

  • Drugs Agatolimod (Primary) ; Aluminium hydroxide (Primary) ; Malaria vaccine (Primary)
  • Indications Falciparum malaria
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 04 Nov 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 28 Aug 2009 Planned end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 25 Nov 2008 Status changed from recruiting to not yet recruiting, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top